Clinical research firm Bio-Images Research has appointed a director of regulatory affairs.
Dr Sarah Connolly, who has been with the Glasgow-based company for the past four years, will take responsibility for GMP, regulatory and ethical approvals.
The appointment is designed to maintain the highest level of ethical and regulatory standards as the company's pipeline of clinical studies steadily increases.
Bio-Images has completed three clinical studies this year and claims to be in the forefront of a small field of providers of gamma scintigraphy imaging services, which allow multi-national pharma companies to outsource some of their clinical research.
Dr Connolly joined the company after completing her PhD in Pharmaceutical Sciences at the University of Strathclyde in 2007.
Bio-Images Research appoints director of regulatory affairs
To maintain highest level of ethical standards as firm expands
You may also like
Research & Development
ProImmune and Roslin Institute collaborate to develop species-specific Ankyron binders for veterinary immunology
Immunological reagents specialist ProImmune has partnered with the University of Edinburgh's Roslin Institute to generate and validate novel species-specific binding proteins for porcine, bovine, avian and salmonid research, addressing a critical shortage of high-quality veterinary immunology reagents
Research & Development
Siemens Healthineers launches blood-based pTau217 and BDTau research assays for Alzheimer's and neurological disease
Siemens Healthineers has made two automated brain biomarker assays available for research use, offering scientists a less invasive blood-based alternative to cerebrospinal fluid testing for investigating neurological disease progression and early Alzheimer's detection
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Research & Development
Atrogi doses first subjects in human trial of exercise-mimicking oral therapy ATR-258
The Swedish biotech has initiated a human trial of ATR-258, a first-in-class oral β2-adrenergic receptor modulator designed to replicate the metabolic effects of exercise, including fat loss and muscle preservation, without the cardiovascular side effects associated with traditional β2-agonists
Drug Delivery
New cancer drug delivery system boosts absorption of Paclitaxel
Researchers from Osaka Metropolitan University have developed a drug-delivery system that effectively delivers anticancer medication to cancerous tissues, potentially offering a solution for therapeutics that are difficult to absorb